Amylin and Biocon collaborate to build up a peptide therapeutic for treating diabetes Amylin Pharmaceuticals, Inc. and Biocon, Limited announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Biocon and Amylin will collaborate to build up the therapeutic potential of the compound and talk about development costs www.priligynorge.com . Research will focus on Amylin’s phybrid technology. A phybrid is normally a peptide hybrid molecule that combines the pharmacological effects of two peptide hormones into a one molecular entity.
An FDA ‘ambiguity’ means patients get unapproved devices A Chicago doctor invented a silicone and metal ring to repair center valves, and implanted them in 150 patients before his new device received FDA acceptance, The Wall Street Journal reports. The episode provides fueled a feud between your doctor, Dr. Patrick McCarthy, and a former collaborator who alleges those sufferers were utilized by him for ‘human experimentation.’ It is also exposed a possibly critical ambiguity in FDA regulations which allows device manufacturers to determine – without independent review – which of their new products require FDA approval and which don’t.